Advances in Chronic Kidney Disease
Volume 11, Issue 2 , Pages 172-183 , April 2004

Blood pressure management in the kidney transplant recipient

  • Matthew R Weir

      Affiliations

    • Division of Nephrology, University of Maryland School of Medicine, Baltimore, MD, USA
    • Corresponding Author InformationAddress correspondence to Matthew R. Weir, MD, Division of Nephrology, University of Maryland School of Medicine, 22 South Greene Street, Suite N3W143, Baltimore, MD 21201 USA

References 

  1. Ponticelli C, Montagnino G, Aroldi A, et al.  Hypertension after renal transplantation. Am J Kidney Dis. 1993;21:73–78
  2. Kasiske BL. Possible causes and consequences of hypertension in stable renal transplant patients. Transplantation. 1987;44:639–643
  3. Ligtenberg G, Hene RJ, Blankestijn PJ, et al.  Cardiovascular risk factors in renal transplant patients (Cyclosporin A versus tacrolimus). J Am Soc Nephrol. 2001;12(2):368–373
  4. Modena FM, Hostetter TH, Salahudeen AK, et al.  Progression of kidney disease in chronic renal transplant rejection. Transplantation. 1991;52:239–2445
  5. Kasiske BL, Heim-Duthoy KL, Tortorice KL, et al.  The variable nature of chronic declines in renal allograft function. Transplantation. 1991;51:330–334
  6. Kasiske BL, Chakkera HA, Roel J. Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol. 2000;11:1735–17437
  7. Levey AS. Controlling the epidemic of cardiovascular disease in chronic renal disease (Where do we start?). Am J Kidney Dis. 1998;32:S5–S13
  8. Brenner BM, Milford EL. Nephron underdosing (A programmed cause of chronic renal allograft failure). Am J Kidney Dis. 1993;21:66–72
  9. Walker M, Harrison-Bernard LM, Cook AK, et al.  Dynamic interaction between myogenic and TGF mechanisms in afferent arteriolar blood flow autoregulation. Am J Physiol Renal Physiol. 2000;279:F858–F865
  10. Just A, Ehmke H, Toktomambetova L, et al.  Dynamic characteristics and underlying mechanisms of renal blood flow autoregulation in the conscious dog. Am J Physiol Renal Physiol. 2001;280:F1062–F1071
  11. Johnson RJ, Schreiner GF. Hypothesis (The role of acquired tubulointerstitial disease in the pathogenesis of salt-dependent hypertension). Kidney Int. 1997;52:1169–1179
  12. Peterson JC, Adler S, Burkart JM, et al.  Blood pressure control, proteinuria, and the progression of renal disease (The modification of diet in renal disease study). Ann Intern Med. 1995;123:754–762
  13. Jafar TH, Stark PC, Schmid CH, et al.  Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int. 2001;60:1131–1140
  14. Kidney Disease Outcome Quality Initiative: K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(suppl):S1–S246
  15. Klahr S, Levey AS, Beck GJ, et al.  The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of diet in renal disease study group. N Engl J Med. 1994;330:877–884
  16. Jafar TH, Schmid CH, Landa M, et al.  Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med. 2001;135:73–87
  17. Klag MJ, Whelton PK, Randall BL, et al.  Blood pressure and end-stage renal disease in men. N Engl J Med. 1996;334:13–18
  18. Opelz G, Wujciak T, Ritz E. Association of chronic kidney graft failure with recipient blood pressure. Collaborative Transplant Study. Kidney Int. 1998;53:217–222
  19. Cosio FG, Dillon JJ, Falkenhain ME, et al.  Racial differences in renal allograft survival (The role of systemic hypertension). Kidney Int. 1995;47:1136–1141
  20. Cosio FG, Pelletier RP, Sedmak DD, et al.  Renal allograft survival following acute rejection correlates with blood pressure levels and histopathology. Kidney Int. 1999;56:1912–1919
  21. Mange KC, Cizman B, Joffe M, et al.  Arterial hypertension and renal allograft survival. JAMA. 2000;283:633–638
  22. Tesi RJ, Elkhammas EA, Henry ML, et al.  Acute rejection episodes (Best predictor of long-term primary cadaveric renal transplant survival). Transplant Proc. 1993;25:901–902
  23. Grimm PC, Nickerson P, Jeffery J, et al.  Neointimal and tubulointerstitial infiltration by recipient mesenchymal cells in chronic renal-allograft rejection. N Engl J Med. 2001;345:93–97
  24. Weir MR. Is chronic calcineurin inhibitor toxicity responsible for long-term deterioration of renal function in transplant recipients?. Transplant Rev. 2003;17:20–30
  25. Coffman TM, Carr DR, Yarger WE, et al.  Evidence that renal prostaglandin and thromboxane production is stimulated in chronic cyclosporine nephrotoxicity. Transplantation. 1987;43:282–285
  26. Scherrer U, Vissing SF, Morgan BJ, et al.  Cyclosporine-induced sympathetic activation and hypertension after heart transplantation. N Engl J Med. 1990;323:693–699
  27. Kon V, Sugiura M, Inagami T. Cyclosporine (Cy) causes endothelin-dependent acute renal failure. Kidney Int. 1990;37:486A; (abstract)
  28. Zhang W, Li JL, Hosaka M, et al.  Cyclosporine A-induced hypertension involves synapsin in renal sensory nerve endings. Proc Natl Acad Sci USA. 2000;97:9765–9770
  29. Curtis JJ. Treatment of hypertension in renal allograft patients (Does drug selection make a difference?). Kidney Int. 1997;63(suppl):S75–S77
  30. Konstam MA, Weir MR. Current perspective on the cardiovascular effects of coxibs. Cleve Clin J Med. 2002;69(suppl 1):SI47–SI52
  31. Weir MR. Renal effects of nonselective NSAIDs and coxibs. Cleve Clin J Med. 2002;69(suppl 1):SI53–SI58
  32. Lewis EJ, Hunsicker LG, Clarke WR, et al.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851–860
  33. Brenner BM, Cooper ME, de Zeeuw D, et al.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–869
  34. Apperloo AJ, de Zeeuw D, de Jong PE. Short-term antiproteinuric response to antihypertensive treatment predicts long-term GFR decline in patients with non-diabetic renal disease. Kidney Int. 1994;45(suppl):S174–S178
  35. Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine (Is this a cause for concern?). Arch Intern Med. 2000;160:685–693
  36. Perazella M, McPhedran P, Kliger A, et al.  Enalapril treatment of posttransplant erythrocytosis (Efficacy independent of circulating erythropoietin levels). Am J Kidney Dis. 1995;26:495–500
  37. Wang AY, Yu AW, Lam CW, et al.  Effects of losartan or enalapril on hemoglobin, circulating erythropoietin, and insulin-like growth factor-1 in patients with and without posttransplant erythrocytosis. Am J Kidney Dis. 2002;39:600–608
  38. Lakkis J, Wei XL, Weir MR. RAAS escape (A real clinical entity that may be important in the progression of cardiovascular and renal disease). Curr Hyperten Rep. 2003;5:408–417
  39. Shihab FS, Bennett WM, Tanner AM, et al.  Angiotensin II blockade decreases TGF-beta1 and matrix proteins in cyclosporine nephropathy. Kidney Int. 1997;52:660–673
  40. Weir MR, Wei C. The role of angiotensin II and TGF-beta on the progression of chronic allograft nephropathy. JRAAS. 2001;2(suppl 1):S188–S190
  41. Stigant CE, Cohen J, Vivera M, et al.  ACE inhibitors and angiotensin II antagonists in renal transplantation (an analysis of safety and efficacy). Am J Kidney Dis. 2000;35:58–63
  42. Chobanian AV, Bakris GL, Black HR, et al.  The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA. 2003;289:2560–2572
  43. Romero JC, Raij L, Granger JP, et al.  Multiple effects of calcium entry blockers on renal function in hypertension. Hypertension. 1987;10:140–151
  44. Weir MR. The clinical utility of calcium antagonists in renal transplant recipients. In:  Epstein M editors. Calcium Antagonists in Clinical Medicine. Philadelphia: Hanley & Belfus, Inc; 2002;p. 603–628
  45. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic (The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)). JAMA. 2002;288:2981–2997
  46. Bakris GL, Copley JB, Vicknair N, et al.  Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int. 1996;50:1641–1650
  47. Bakris GL, Weir MR, DeQuattro V, et al.  Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int. 1998;54:1283–1289
  48. Bakris GL, Weir MR, Shanifar S, et al.  Effects of blood pressure level on progression of diabetic nephropathy (Results from the RENAAL study). Arch Intern Med. 2003;163:1555–1565
  49. Heeg JE, de Jong PE, van der Hem GK, et al.  Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril. Kidney Int. 1989;36:272–279

PII: S1073-4449(04)00005-6

doi: 10.1053/j.arrt.2004.01.004

Advances in Chronic Kidney Disease
Volume 11, Issue 2 , Pages 172-183 , April 2004

Article Tools

* Image Usage & Resolution